Prevention of hemorrhagic complications after operations performed on the background of anticoagulant therapy
AbstractBackground. According to the literature, the frequency of pacemaker (PM) pocket hematomas ranges from 0.2 to 16%. In patients on antiplatelet or anticoagulant therapy, the incidence of PM pocket hematomas increases to 2–20%. Hemorrhagic complications often prolong the length of hospital stay, may require repeated surgical interventions and, most importantly, significantly increase the risk of infection.
Objective. This study was undertaken to investigate the risk factors for hemorrhagic complications after permanent PM implantation, their relationship with the baseline parameters of the hemostasis system and the possibilities of prevention using an incomplete silver salt of polyacrylic acid.
Material and methods. The patients enrolled in our prospective, single-center study were assigned to the experimental and control groups by block randomization. In the experimental group, the hemostatic agent incomplete polyacrylic acid silver salt Hemoblock® was used during PM placing. Before surgery, all patients underwent peripheral venous blood sampling to determine a series of parameters of the patient’s hemostasis system: levels of fibrinogen, P-selectin, soluble fibrin-monomer complexes, D-dimer, type 1 plasminogen activator inhibitor, activity of blood coagulation factors II (FII), V (FV), VII, VIII, IX, X (FX), XI (FXI), XII, von Willebrand factor, plasminogen, antithrombin III, protein C, additionally determining the parameters of total blood count: the level of platelets, thrombocrit, platelet distribution width, mean platelet volume. The postoperative wound was examined daily, with an ultrasound examination of the soft tissues of the PM pocket area performed on POD 3-5. After 1 month, the patients visited the research center for the final examination of the postoperative wound and testing of PM parameters.
Results and discussion. The follow-up period was completed by 91 patients (44 of the experimental group and 47 of the control group). In the experimental group, 9 (20.5%) patients were found to have soft tissue hematomas, whereas in the control group, 25 (53.2%) patients developed soft tissue hematomas and 6 (12.8%) PM pocket hematomas, with the differences being statistically significant (p=0.001 and p=0.027). Patients with hemorrhagic complications had lower activity of factors FII (p=0.007), FV (p=0.035), FX (p=0.012), FXI (p=0.048). According to multivariate analysis, the factors reducing hemorrhagic complications after PM implantation on the background of anticoagulant therapy turned out to be the use of apixaban as an anticoagulant drug (OR 0.25, 95% CI 0.07–0.889, р=0.032) and the use of incomplete silver salt of polyacrylic acid (OR 0.191, 95% CI 0.072–0.504, р=0.001). The chances of developing hemorrhagic complications increased against the background of reduced FXI activity (OR 0.975, 95% CI 0.951–0.999, р=0.044).
Conclusion. The use of incomplete polyacrylic acid silver salt proved to be an effective and safe method of preventing hematomas after PM placing in patients on anticoagulant therapy. It was found that patients with hemorrhagic complications initially had lower FII, FV, FX and FXI activity compared to other patients. In addition, the results of multivariate analysis proved that low FXI activity increased the chances of developing hemorrhagic complications.
Funding. The study was financed from the extra-budgetary funds of the Federal State Budgetary Educational Facility of Higher Education “Ryazan State Medical University” of the RF Ministry of Public Health. The hemostatic agent incomplete silver salt of polyacrylic acid (Hemoblock®) was provided by the Autonomous Nonprofit Organization “Moscow Regional Blood Research Institute” free of charge.
Conflict of interest. The authors declare no conflicts of interest.
Authors’ contribution. Study conception and design – Kalinin R.E., Suchkov I.A., Zhurina O.N.; data collection and handling – Povarov V.O., Mzhavanadze N.D.; statistical processing – Povarov V.O., Mzhavanadze N.D.; draft manuscript preparation – Povarov V.O.; manuscript revision – Mzhavanadze N.D., Suchkov I.A.
For citation: Povarov V.O., Kalinin R.E., Mzhavanadze N.D., Zhurina O.N, Suchkov I.A. Prevention of hemorrhagic complications after operations performed on the background of anticoagulant therapy. Angiology and Vascular Surgery. Journal named after Academician A.V. Pokrovsky. 2023; 29 (4): 30–9. DOI: https://doi.org/10.33029/1027-6661-2023-29-4-30-39
Keywords:pacemaker; anticoagulant therapy; hematoma; hemostasis system; hemostatic therapy
References
1. Burri H., Starck C. EHRA expert consensus statement and practical guide on optimal implantation technique for conventional pacemakers and implantable cardioverter-defibrillators: endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin-American Heart Rhythm Society (LAHRS). Europace. 2021; 23 (7): 983–1008. DOI: https://doi.org/10.1093/europace/euaa367
2. Song J., Tark A., Larson E.L. The relationship between pocket hematoma and risk of wound infection among patients with a cardiovascular implantable electronic device: An integrative review. Heart & Lung. 2020; 49 (1): 92–98. DOI: https://doi.org/10.1016/j.hrtlng.2019.09.009
3. Essebag V., Verma A., Healey J.S., et al. Clinically Significant Pocket Hematoma Increases Long-Term Risk of Device Infection: BRUISE CONTROL INFECTION Study. Journal of the American College of Cardiology. 2016; 67 (11): 1300–1308. DOI: https://doi.org/10.1016/j.jacc.2016.01.009
4. Birnie D.H., Healey J.S., Wells G.A., et al. Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thromboembolic events (BRUISE CONTROL-2). European Heart Journal. 2018; 39 (44): 3973–3979. DOI: https://doi.org/10.1093/eurheartj/ehy413
5. Martin A.C., Weizman O., Sellal J.M., et al. Impact of peri-procedural management of direct oral anticoagulants on pocket haematoma after cardiac electronic device implantation: the StimAOD multicentre prospective study. Europace. 2023; 25 (5): euad057. DOI: https://doi.org/10.1093/europace/euad057
6. Turagam M.K., Nagarajan D.V., Bartus K., et al. Use of a pocket compression device for the prevention and treatment of pocket hematoma after pacemaker and defibrillator implantation (STOP-HEMATOMA-I). Journal of Interventional Cardiac Electrophysiology. 2017; 49 (2): 197–204. DOI: https://doi.org/10.1007/s10840-017-0235-9
7. Kalinin R.E., Suchkov I.A., Povarov V.O., et al. Hemostasis system in patients with bradycardias after the implantation of dual-chamber pacemakers. I.P. Pavlov Russian Medical Biological Herald. 2021; 29 (4): 497–504. DOI: https://doi.org/10.17816/PAVLOVJ79285 (in Russian)
8. Sang Y., Roest M., de Laat B., et al. Interplay between platelets and coagulation. Blood Reviews. 2021; 46: 100733. DOI: https://doi.org/10.1016/j.blre.2020.100733
9. Versteeg H.H., Heemskerk J.W., Levi M., Reitsma P.H. New fundamentals in hemostasis. Physiological Reviews. 2013; 93 (1): 327–58. DOI: https://doi.org/10.1152/physrev.00016.2011
10. Podoplelova N.A., Sveshnikova A.N., Kotova Y.N., et al. Coagulation factors bound to procoagulant platelets concentrate in cap structures to promote clotting. Blood. 2016; 128 (13):1745–1755. DOI: https://doi.org/10.1182/blood-2016-02-696898
11. Risman R.A., Kirby N.C., Bannish B.E., et al. Fibrinolysis: an illustrated review. Research and Practice in Thrombosis and Haemostasis. 2023; 7 (2): 100081. DOI: https://doi.org/10.1016/j.rpth.2023.100081
12. Jing S., Hu S., Ma S. Analysis of postoperative complications and risk factors in patients with permanent pacemaker implantation. Journal of Thoracic Disease. 2020; 12 (10): 5980–5985. DOI: https://doi.org/10.21037/jtd-20-2913
13. Kalinin R.E., Suchkov I.A., Povarov V.O., Plotkin A.V. Local hemostatic drug application for prophylaxis of pacemaker pocket hematoma. Science of the young (Eruditio Juvenium). 2021; 9 (3): 397–406. DOI: https://doi.org/10.23888/HMJ202193397-406 (in Russian)
14. Kalinin R.E., Suchkov I.A., Povarov V.O., et al. Local hemostatic drug application during pacemaker implantation in patients on anticoagulant therapy. Russian Journal of Thoracic and Cardiovascular Surgery. 2022; 2 (64): 177–183. DOI: https://doi.org/10.24022/0236-2791-2022-64-2-177-183 (in Russian)